Willemijn S.M.E. Theelen

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

Willemijn S.M.E. Theelen, Heike Peulen, Ferry Lalezari et al. · JAMA Oncology · 2019 · 984 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

Willemijn S.M.E. Theelen, Dawei Chen, Vivek Verma et al. · The Lancet Respiratory Medicine · 2020 · 558 citations

Medicine, Oncology, Pharmacotherapy +13

Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer

Tony Mok, Yi‐Long Wu, M. Ahn et al. · QUT ePrints (Queensland University of Technology) · 2017 · 474 citations · Full text

Medicine, Oncology, Pharmacology +16

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han et al. · Annals of Oncology · 2020 · 276 citations · Full text

Medicine, Oncology, Pharmacology +15